The role of LFA-1 in the lysis of bladder cancer cells by bacillus Calmette-Guerin and interleukin 2-activated killer cells

Urological Research

Volumn 30, Issue 4, 2002, Pages 233-239

  Suttmann, Henrik ^a   Jocham, Dieter ^a   Bohle, Andreas ^a   Brandau, Sven ^b  

^a Children's Hospital   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

BCG; Bladder cancer; Cellular cytotoxicity; IL 2; LFA 1

Indexed keywords

BCG VACCINE; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CELL MEDIATED CYTOTOXICITY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOKINE ACTIVATED KILLER CELL; MONONUCLEAR CELL; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; TARGET CELL;

ANTIGENS, CD11A; ANTIGENS, CD18; CELL ADHESION; HUMANS; INTERLEUKIN-2; KILLER CELLS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MONOCYTES; MYCOBACTERIUM BOVIS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0036928740     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-002-0268-z     Document Type: Article

References (43)

1. Alexandroff A, Jackson AM, O'Donnell M, James K “1999” BCG immunotherapy of bladder cancer: 20 years on. Lancet 353: 1689
2. Axberg I, Ramstedt U, Patarroyo M, Beatty P, Wigzell H “1987” Inhibition of natural killer cell cytotoxicity by a monoclonal antibody directed against adhesion-mediating protein gp 90 “CD 18”. Scand J Immunol 26: 547
3. Belldegrun A, Uppenkamp IK, Rosenberg SA “1988” Anti-tumor reactivity of human lymphokine activated killer “LAK” cells against fresh and cultured preparations of renal cell cancer. J Urol 139: 150
4. Berke G, Gabison D, Feldman M “1975” The frequency of effector cells in populations containing cytotoxic T lymphocytes. Eur J Immunol 5: 813
5. Blanchard DK, Hall RE, Dieu JY “1990” Role of CD18 in lymphokine activated killer “LAK” cell-mediated lysis of human monocytes: comparison with other LAK targets. Int J Cancer 45: 312
6. Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad H-D “1990” Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53
7. Bohle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad H-D “1990” Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol 144: 59
8. Bohle A, Thanhauser A, Ulmer AJ, Ernst M, Flad H-D, Jocham D “1993” Dissecting the immunobiological effects of bacillus Calmette-Guerin “BCG” in vitro: evidence of a distinct BCG-activated killer “BAK” cell phenomenon. J Urol 150: 1932
9. Brandau S, Bohle A “2001” Activation of NK cells by Bacillus Calmette Guerin “BCG”. Eur Urol 39: 518
10. Brandau S, Suttmann H, Flad H-D, Jocham D, Bohle A “2000” Killing of Fas ligand-resistant renal carcinoma cells by interleukin-2- and BCG-activated effector cells. Cancer Immunol Immunother 49: 369
11. Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad H-D, Bohle A “2000” Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 6: 3729
12. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, Bohle A “2001” NK cells are essential for effective BCG-immunotherapy. Int J Cancer 92: 697
13. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J “1973” Established cell line of urinary bladder carcinoma “T24” containing tumour-specific antigen. Int J Cancer 11: 765
14. Campbell SC, Tanabe K, Alexander JP, Edinger M, Tubbs RR, Klein EA “1994” Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects. J Urol 151: 1385
15. de Boer EC, de Jong WH, van der Meijden APM, Steerenberg PA, Witjes F, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ “1991” Presence of activated lymphocytes in the urine of patients after intravesical immunotherapy with bacillus Calmette-Guerin. Cancer Immunol Immunother 33: 411
16. de Landazuri MO, Herberman RB “1972” Specificity of cellular immune reactivity to virus-induced tumours. Nat New Biol 238: 18
17. Donskov F, Basse PH, Hokland M “1996” Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. Nat Immun 97: 134
18. Durek C, Brandau S, Ulmer AJ, Flad H-D, Jocham D, Bohle A “1999” Bacillus-Calmette-Guerin “BCG” and 3D tumors: an in vitro model for the study of adhesion and invasion. J Urol 162: 600
19. El-Demiry MIM, Smith G, Ritchie AWS, James K, Cumming JA, Hargreave TB, Chisholm GD “1987” Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol 60: 543
20. Esavaranathan K, Jackson AM, Alexandrov A, James K “1993” The expression of ICAM-1 & ICAM-2 in bladder cancer cells. J Urol 149: A230
21. Gahmberg CG “1997” Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Curr Opin Cell Biol 9: 643
22. Grimm EA, Rosenberg SA “1984” The human lymphokine-activated killer cell phenomenon. Lymphokines 9: 279
23. Herr HW, Laudone VP, Whitmore WF Jr “1987” An overview of intravesical therapy for superficial bladder tumors. J Urol 138: 1363
24. Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD “1992” Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1. Immunology 76: 286
25. Jackson AM, Alexandroff AB, McIntyre M, Esuvaranathan K, James K, Chisholm GD “1994” Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol 47:309
26. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA “1991” A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205
27. Larson RS, Springer TA “1990” Structure and function of leukocyte integrins. Immunol Rev 114: 181
28. Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER “1996” Perforin, Fas Ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 157: 1919
29. Leibold WB, Bridge S “1979” 75Se-release: a short and long term assay system for cellular cytotoxicity. Z Immun Forsch 155: 287
30. Maenpaa A, Jaaskelainen J, Carpen O, Patarroyo M, Timonen T “1998” Expression of integrins and other adhesion molecules on NK cells: impact of IL-2 on short- and long-term cultures. Int J Cancer 53: 850
31. Morales A, Eidinger D, Bruce AW “1976” Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180
32. Ortaldo JR, Mason A, Overton R “1986” Lymphokine activated killer cells: analysis of progenitors and effctors. J Exp Med 164: 1193
33. Ratliff TL, Gillen DP, Catalona WJ “1987” Requirement of a thymus-dependent immune response for BCG- mediated anti-tumor activity. J Urol 137: 155
34. Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona WJ “1993” T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150: 1018
35. Reiß K, Brandau S, Ulmer AJ, Flad H-D, Jocham D, Bohle A “1999” BCG-immunotherapy of superficial bladder cancer: BCG-induced activation of MNCs is regulated by cytokines. Eur Urol 36: A476
36. Rosenberg SA “1988” Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9: 58
37. Sander B, Damm O, Gustafsson B, Andersson U, Hakansson L “1996” Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical Bacillus Calmette-Guerin. J Urol 156: 536
38. Shemtov MM, Cheng DLW, Kong L, Shu W-P, Sassaroli M, Droller MJ, Liu BCS “1995” LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy. J Urol 154: 269
39. Springer TA “1990” Adhesion receptors of the immune system. Nature 346: 425
40. Thanhauser A, Bohle A, Flad H-D, Ernst M, Mattern T, Ulmer AJ “1993” Induction of bacillus Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37: 105
41. Thanhauser A, Bohle A, Schneider B, Reiling N, Mattern T, Ernst M, Flad H-D, Ulmer AJ “1995” The induction of bacillus Calmette-Guerin-activated killer cells requires the presence of monocytes/macrophages and T-helper type 1 cells. Cancer Immunol Immunother 40: 103
42. Timonen T, Helander TS “1997” Natural killer cell-target cell interactions. Curr Opin Cell Biol 9: 667
43. Timonen T, Gahmberg CG, Patarroyo M “1990” Participation of CD11a-c/CD18, CD2 and RGD-binding receptors in endogenous and interleukin-2-stimulated NK activity of CD3-negative large granular lymphocytes. Int J Cancer 46: 1035